How many dopamine receptors are there

New York: Raven Press; Carlsson A, Lindquest M. Effects of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. Utilization therapeutique psychiatrique d'une phenothiazine d'action centrale elective. Ann Med Psychol Paris. Ehrinnger H, Hornykiewicz o. Klin Wochenschr. PET analysis of central D1 and D2 receptor occupancy in patients treated with classical neuroleptics and clozapine.

Arch Gen Psychiatry. No D2 receptor increase in PET study of schizophrenia. Central D2 receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Cocaine and other stimulants. N Engl J Med. Recent advances in the molecular biology of dopamine receptors. Ann Rev Neurosci. Textbook of Neuropsychiatry. Washington: American Psychiatric Press; The Molecular Foundations of Psychiatry. Pharmacology of risperidone R64 , a new antipsychotic with serotonin-S2 and dopamine-D2 antagonist properties.

J Pharm Exper Therap. Multiple receptors for dopamine. Kosten TR. Pharmacotherapies for cocaine abuse: neurobiological abnormalities reversed with drug intervention. Psychiatr Times. Meltzer H. The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry. Meltzer HY. Duration of clozapine trial in neuroleptic-resistant schizophrenia.

Arch Gen Psychiatry letter. Dopamine receptor genes: new tools for molecular psychiatry. J Psychiatr Neurosci. O'Dowd BF. Structure of dopamine receptors. J Neurochem. Onigini E, Longo VG. Dopamine receptor subtypes and arousal. Int Rev Neurobiol. Dopamine D4 receptors elevated in schizophrenia. The dopamine D3 receptor: from cloning to characterization of the native receptor in the brain.

Abstr 7th International Catecholamine Symposium. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. The role of cocaine in dopamine use and abuse. Psychiatr Ann. Dopamine Receptors in the Human Brain. May 1, Jeffrey M. Targeting the dopamine D3 receptor: an overview of drug design strategies.

Expert Opin. Drug Discovery 11 7 , — Coyle, J. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. Dialogues Clin. PubMed Abstract Google Scholar. Psychiatry doi: Daskalakis, A. Evidence for prefrontal cortex hypofunctioning in schizophrenia through somatosensory evoked potentials.

David, O. De Vries, L. Delevich, K. Desai, S. Combination of behaviorally sub-effective doses of glutamate NMDA and dopamine D1 receptor antagonists impairs executive function.

Brain Res. Dreyer, J. Influence of phasic and tonic dopamine release on receptor activation. Ebersole, B. PloS One 10 11 , e El Mestikawy, S. From glutamate co-release to vesicular synergy: vesicular glutamate transporters. Enge, S. Cumulative Dopamine Genetic Score predicts behavioral and electrophysiological correlates of response inhibition via interactions with task demand.

Eshel, N. Arithmetic and local circuitry underlying dopamine prediction errors. Nature , — Fan, L. Haloperidol bound D2 dopamine receptor structure inspired the discovery of subtype selective ligands. Fareri, D. Altered ventral striatal-medial prefrontal cortex resting-state connectivity mediates adolescent social problems after early institutional care.

Faron-Gorecka, A. Genetic variants in dopamine receptors influence on heterodimerization in the context of antipsychotic drug action. Ferraro, M. Multi-target dopamine D3 receptor modulators: Actionable knowledge for drug design from molecular dynamics and machine learning. Ferre, S. Foster, D. Neuron 94 3 , — Frankle, W. Fusar-Poli, P. Striatal presynaptic dopamine in schizophrenia, Part I: meta-analysis of dopamine active transporter DAT density. Gienger, M.

Girgenti, M. PloS One 7 2 , e Girgis, R. A positron emission tomography occupancy study of brexpiprazole at dopamine D2 and D3 and serotonin 5-HT1A and 5-HT2A receptors, and serotonin reuptake transporters in subjects with schizophrenia.

Neuropsychopharmacology 45 5 , — Gonzalez-Burgos, G. Grace, A. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression.

Gray, D. Impaired beta-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor. Grea, H. Gross, J. Regulator of G protein signaling modulates the dopamine transporter in ventral striatum and locomotor responses to psychostimulants.

Guitart, X. Guma, E. Role of D3 dopamine receptors in modulating neuroanatomical changes in response to antipsychotic administration. Gutierrez-Arenas, O. Segregation and crosstalk of D1 receptor-mediated activation of ERK in striatal medium spiny neurons upon acute administration of psychostimulants. PloS Comput. Hall, A.

Hamid, A. Mesolimbic dopamine signals the value of work. Han, S. Distinct striatum pathways connected to salience network predict symptoms improvement and resilient functioning in schizophrenia following risperidone monotherapy. Harada, A. He, D. Hikima, T. Presynaptic D1 heteroreceptors and mGlu autoreceptors act at individual cortical release sites to modify glutamate release.

Hu, J. Brain 3, Huang, R. Pharmacology 92 , 84— Huang, Y. Defining cognitive and functional profiles in schizophrenia and affective disorders. BMC Psychiatry 20 1 , Hubner, H. Structure-guided development of heterodimer-selective GPCR ligands. Hunger, L. Hunnicutt, B. A comprehensive excitatory input map of the striatum reveals novel functional organization.

Elife 5. Hwang, R. Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration. Psychiatry 37 1 , 62— Iino, Y. Dopamine D2 receptors in discrimination learning and spine enlargement. Jackson, M. Psychiatry 87 8 , — Jacobi, A. Jezequel, J. Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients.

Trends Neurosci. Jiang, S. Kaczor, A. The dopamine D2 receptor dimer and its interaction with homobivalent antagonists: homology modeling, docking and molecular dynamics.

Karadurmus, D. Kasai, R. Cell Biochem. Kern, A. Cell 5 , — Kesby, J. Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Psychiatry 8 1 , Khlghatyan, J. Cortex 29 9 , — Kim, S.

Koblan, K. N Engl. Kontaris, I. Kos, M. Dopamine perturbation of gene co-expression networks reveals differential response in schizophrenia for translational machinery. Kotarska, A. Cell adhesion molecule close homolog of L1 binds to the dopamine receptor D2 and inhibits the internalization of its short isoform. Ladepeche, L. Lak, A. Neuron 4 , — Lane, J. Distinct inactive conformations of the dopamine D2 and D3 receptors correspond to different extents of inverse agonism. Elife 9. Lebowitz, J.

Heterogeneity of dopamine release sites in health and degeneration. Leggio, G. The epistatic interaction between the dopamine D3 receptor and dysbindin-1 modulates higher-order cognitive functions in mice and humans. Leo, D. Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: role of D2 dopamine autoreceptors. Neuropharmacology 81, — Li, A. A neuroimaging biomarker for striatal dysfunction in schizophrenia. Liu, X. Neuron 61 3 , — Lohani, S. Burst activation of dopamine neurons produces prolonged post-burst availability of actively released dopamine.

Neuropsychopharmacology 43 10 , — Cell Rep. Lucarelli, M. Cell Neurosci. Lukasiewicz, S. Dopamine D2 and serotonin 5-HT1A receptor interaction in the context of the effects of antipsychotics - in vitro studies. Luo, Y. Nucleus accumbens controls wakefulness by a subpopulation of neurons expressing dopamine D1 receptors.

Ma, J. Graph Model. Madras, B. History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia.

Marcott, P. Phasic dopamine release drives rapid activation of striatal D2-receptors. Neuron 84 1 , — Neuron 98 3 , —87 e4. Matera, C. McCutcheon, R. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry 19 1 , 15— Meier, M. The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices.

Min, C. N-linked Glycosylation on the N-terminus of the dopamine D2 and D3 receptors determines receptor association with specific microdomains in the plasma membrane. Acta 1 , 41— Mitelman, S. Dopamine receptor density and white mater integrity: 18 F-fallypride positron emission tomography and diffusion tensor imaging study in healthy and schizophrenia subjects.

Brain Imaging Behav. Mohebi, A. Dissociable dopamine dynamics for learning and motivation. Nature , 65— Molinaro, L. Role of presynaptic phosphoprotein synapsin II in schizophrenia. World J. Psychiatry 5 3 , — Moritz, A. Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Cell Signal. Nai, Q. Psychiatry 67 3 , — Nair, A. Modeling intracellular signaling underlying striatal function in health and disease. The high efficacy of muscarinic M4 receptor in D1 medium spiny neurons reverses striatal hyperdopaminergia. Neuropharmacology , 74— Nakao, K.

Nicoletti, F. Nishi, A. Mechanisms for the modulation of dopamine d 1 receptor signaling in striatal neurons. Ohira, K. Dopamine as a growth differentiation factor in the mammalian brain. Neural Regener. Oishi, K. Genetic combination risk for schizophrenia. Onishi, T. Pal, R. Inclusion of enclosed hydration effects in the binding free energy estimation of dopamine D3 receptor complexes. PloS One 14 9 , e Papenberg, G.

Cortex 30 3 , — Park, S. Neuropsychopharmacology 41 3 , — Park, J. Pei, Y. Periclou, A. Perreault, M. The dopamine d1-d2 receptor heteromer in striatal medium spiny neurons: evidence for a third distinct neuronal pathway in Basal Ganglia. Petralia, M. Genes Basel 11 4 , Petty, A. NPJ Schizophr. Potkin, S. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research.

Provenzano, F. Pulido, D. Purves-Tyson, T. Putative presynaptic dopamine dysregulation in schizophrenia is supported by molecular evidence from post-mortem human midbrain.

Psychiatry 7 1 , e Qian, M. ChemMedChem 13 9 , — Quintana, C. A fresh look at cortical dopamine D2 receptor expressing neurons. Rampino, A. Psychiatry 9, Rao, N. Ren, K. Neural Circuits 11, Reynolds, L. Psychiatry 83 2 , — Activation of dopamine receptors can either lead to an excitatory D1, D5 or inhibitory D2, D3, D4 response in the brain Brown, When the excitatory receptors are activated, this activates adenylyl cyclase, a regulatory enzyme, which then increases the concentration of cAMP inside the cell Dopamine Receptor, Activation of D2-like receptors generates an inhibitory response by preventing the formation of cAMP by inhibiting the adenylyl cyclase enzyme Dopamine Receptor, Many psychostimulants including cocaine and methamphetamine produce a feeling of euphoria by the increase of dopamine in the neuronal synapse Brown, In a normal cell, dopamine is taken back up into the presynaptic cell to recycle, but cocaine binds to the dopamine receptor on the presynaptic cell to block the reuptake by the dopamine receptor causing an increase in dopamine in the synapse "How Does In addition to preventing the reuptake of dopamine, methamphetamine increases the secretion of dopamine from the receptors by an unknown mechanism, which creates an even more intense feeling of euphoria Kish, One of the reasons why methamphetamine is so dangerous is that not only does it affect dopamine, but it also promotes the release of other monoamine neurotransmitters including norepinephrine, epinephrine, and serotonin.

The release of excess epinephrine and norepinephrine overstimulate the sympathetic nervous system which can lead to high blood pressure and increased heart rate leading to cardiac arrest and death Kish, In the United States, approximately 9.

Specifically, the use of a wide range of substances like alcohol and illicit drugs interact with dopamine receptors and induce an abnormally high level of dopamine to flood the brain. Because dopamine is the primary neurotransmitter in the human reward pathway, the brain begins to associate alcohol or other substance that cause the influx with the huge chemical reward.

Initial use is usually caused by the desire to obtain their positive reaction but addiction occurs when the brain no longer functions optimally without the dopamine surge caused by the substance.

Because addiction is not only caused by psychological desire but also biological desire it rapidly becomes a detrimental disease to those who suffer. Malfunction of dopamine receptors also plays a role in a wide array of other neurological problems. There is a delicate balance that must be maintained for the human brain to function at the peak of its ability.

In the case of schizophrenia it is currently accepted that a wide range of the positive symptoms, including hallucinations and delusions, originate because of an increased level of subcortical dopamine which in turn augments the D2 receptors and leads to even more release in areas of the brain like the nucleus accumbens.

Some of the negative effects which include inability to form sentences and lack of outward motivation are hypothesized to be triggered by the reduced activation of D1 receptors Brisch et al,